Publication: 3479

Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials
      QxMD      Google Scholar   
Citation:
J Clin Oncol vol 36 (16) 1603-10
Year:
2018
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
2991  
Children:
None
Program:
OGC
Primary Committee:
Lymphoma
Sec. Committees:
   
Pharmas:
 
Grants:
P30 CA086862, P50 CA097274, U01 CA195568  
Corr. Author:
Matthew J. Maurer 
Authors:
                                                         
Networks:
 
Study
Alliance-A151814
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
N/A
Keywords:
ORIGINAL REPORTS, Hematologic Malignancy